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had a mean (SD) age of 43.0 (13.4) and was 95.7% female. Exact
agreement between organ involvement ranged from 47.8% for
blood counts to 86.6% for blood clots. There was signiﬁcant
agreement for involvement of skin/hair/scalp (K = 0.46), kidneys
(K = 0.55), brain (K = 0.54), and blood clots (K = 0.60). Poor
agreement was noted for abnormal blood counts (K = 0.08) and
joint involvement (K = 0.06). CONCLUSION: Similar to studies
of patient-physician agreement on quality of life, stronger agree-
ment between patient and physician assessment was reported for
more physical manifestations of disease. Results suggest there is
opportunity to improve patient management through education
and patient-provider communication.
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OBJECTIVES: To evaluate the impact of product enhancements
such as a new autoinjector (Rebiject II) and ﬁner needles upon
adherence to therapy for patients receiving subcutaneous (sc) Inter-
feron-beta-1a (IFNB-1a) 44 mcg tiw. Injection site reactions (ISRs)
are a common cause of treatment discontinuation in patients with
multiple sclerosis (MS). Support organizations such as the MS Life-
Lines program may help patients manage ISRs, however, simpliﬁ-
cation of the injection process via autoinjectors and ﬁner gauge
needles may also help to decrease ISRs. METHODS: Data were
gathered by the MS LifeLines program between August 2003 and
November 2004 (before product enhancements) and again
between December 2004 and March 2006 (after product enhance-
ments). Patients were contacted by nurse educators at regular inter-
vals and asked a series of questions to determine whether they were
adherent to therapy or had discontinued, and, if they had discon-
tinued, why they had done so. Reasons for discontinuation were
recorded and divided into 3 categories: ISRs, pain and/or burning
at the injection site, or other reasons. RESULTS: Between August
2003 and November 2004, 11,783 total patients received subcu-
taneous (sc) IFNB-1a 44 mcg tiw. Of the 2079 patients who dis-
continued therapy 190 (9.1%) were due to ISRs and 175 (8.4%)
were due to pain and/or burning at the injection site. Between
December 2004 and March 2006, when Rebiject II and ﬁner gauge
needles were incorporated, 12,968 total patients received sc IFNB-
1a 44 mcg tiw. Of the 1780 (13.7%) who discontinued therapy 99
(5.6%) were due to ISRs and 33 (1.9%) were due to pain and/or
burning at the injection site. CONCLUSION: These results demon-
strate that product enhancements have dramatically decreased dis-
continuation of therapy due to overall ISRs and injection pain or
burning in patients administering (sc) IFNB-1a 44 mcg tiw. The
decreased discontinuation to therapy may potentially improve
long-term outcomes.
NEUROLOGICAL DISORDERS—Methods & Concepts
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OBJECTIVES: To examine differences in the prevalence of other
diseases for patients with and without Alzheimer’s Disease (AD),
and the independent effect of AD on cost, beyond the expected
cost of treating other medical conditions. METHODS: We used
MarketScan Medicare Supplemental and Coordination of Bene-
ﬁts claims data, 2003–2004, for over-age-65 individuals with
Medicare and employer-sponsored plans including drug beneﬁts.
We identiﬁed AD patients by an AD diagnosis or an exclusively
prescribed AD medication in 2003, and selected a demographi-
cally-matched, non-demented Control (3 : 1 ratio to AD). Apply-
ing Diagnostic Cost Groups (DCGs), a comprehensive disease
classiﬁcation and prediction system, we calculated a prospective
relative risk score (RRS) that predicts 2004 costs from non-AD
illnesses in 2003; the mean RRS of all individuals enrolled for
all of 2003 and ≥1 month in 2004 was set to 1.00. We used
regression to estimate AD’s independent effect on cost overall
and among patients with selected non-AD conditions. RESULTS:
The AD Cohort (n = 25,109) is sicker (mean RRS 1.23 vs. 1.04)
than the Controls (n = 75,327); they have more comorbidities
(mean of 8.1 unique medical conditions vs. 6.5) and 34% higher
costs ($13,936 vs. $10,369). However, excess annual costs
attributable to AD are estimated to be only $2307, with outpa-
tient pharmacy being the key driver ($1711 in excess costs). The
AD Cohort has more diabetes, heart, mental health, injuries, vas-
cular, and urinary problems. For patients with certain comor-
bidities (such as, anxiety disorders), excess costs attributable to
AD reach $6000. CONCLUSION: AD patients are sicker than
demographically similar patients, yet cost even more than is
accounted for by their excess morbidity. Much of the additional
cost is due to greater use of outpatient pharmaceuticals.
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OBJECTIVES: To compare the psychometric properties of
migraine speciﬁc health related quality of life instruments based
on McHorney and Tarlov (1995). METHODS: Eleven instru-
ments were identiﬁed based on the following criteria: at least one
peer reviewed publication of the instrument; instrument focus on
HRQOL; psychometric data and instrument availability. Identi-
ﬁed instruments were evaluated based on the McHorney and
Tarlov’s (1995) criteria for individual decision making and
included: item information; administration time (practicality);
instrument breadth; depth (ﬂoor and ceiling effects <15%); 
reliability (internal consistency and test-retest) and validity.
RESULTS: Five migraine speciﬁc health related quality of life
Instruments were identiﬁed: the Migraine Speciﬁc Quality of Life
Questionnaire (MSQ); Migraine Disability Assessment Score
(MIDAS); 24 hr Migraine Speciﬁc Quality of Life Questionnaire
(MQoLQ); Migraine Speciﬁc Quality of Life Measure (MSQOL)
and the Headache Impact Test-6 (HIT-6). Ideal psychometric
properties were not shown by any of the ﬁve instruments evalu-
ated based on study criteria. This was in part due to lacking 
psychometric data in addition to failure to meet study criteria.
For example, MSQ was the only questionnaire available with
reported depth and internal consistency data. MSQ, MIDAS,
MQoLQ were the most frequently used questionnaires. MSQ
was notable for the most extensive psychometric data to support
the scale including adequate item information, breadth, depth
(ﬂoor and ceiling effects <10%) and validity (multitrait-multi-
method, convergent, known groups and conﬁrmatory factor
analysis). Although internal consistency for all the dimensions of
MSQ (α = 0.86–0.96) was adequate for group level decision
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making (α > 0.7), some of the dimensions did not meet study cri-
teria for individual decision making. CONCLUSION: The Study
results do not support the use of any of the evaluated instru-
ments for individual decision making. Based on available psy-
chometric data, use of MSQ for group level decision making for
clinical trials is recommended.
NEUROLOGICAL DISORDERS—
Patient-Reported Outcomes
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OBJECTIVES: Examine medication side-effects and patients’
adherence to disease modifying medications. METHODS: A
two-wave Internet survey was conducted by Harris Interactive
among patients with multiple sclerosis in 2006, and 332 subjects
from the ﬁrst wave were analyzed (response rate 31%).
RESULTS: Respondents were generally satisﬁed with the effec-
tiveness of therapy, reporting 5 ± 1.0 (mean ± standard devia-
tion) with 6 the most satisﬁed. Over half of subjects (53.8%)
reported experiencing side effects. Frequent side effects were
head/muscle ache (36.8%), injection site reaction (31.9%),
fatigue (26.3%), fever (18.4%), pain (15.2%) and depression
(10.5%). The majority of side effects began <1 day after start-
ing therapy: 81.8% of head/muscle ache, 59.3% of site reaction
and 56.7% of fatigue began in <1 day. The majority of fever
(74.6%) lasted <1 day. The median duration of injection site
reaction was 3 days, head/muscle ache was 1 day, and fatigue
was 1 day. Over one-third (36.6%) of subjects reported forget-
ting (Horne scale) to take disease-modifying agents. CONCLU-
SION: Patients commonly reported side effects due to their
therapy with disease modifying agents. This study provides a
foundation for future research of determinants of MS patients’
adherence behavior.
PND25
A REVIEW OF HEALTH RELATED QUALITY OF LIFE
INSTRUMENTS USED IN CHILDREN AND ADOLESCENTS
WITH EPILEPSY
Rane PB, Kamal KM
Duquesne University, Pittsburgh, PA, USA
OBJECTIVES: Epilepsy represents the most prevalent and
serious neurological condition affecting children in their devel-
oping years. Epilepsy has a signiﬁcant impact on the health-
related quality of life (HRQoL) of children and their families. In
the last decade, signiﬁcant advances have been made to measure
HRQoL in children and adolescents with epilepsy; resulting in
the development of several HRQoL instruments. The aim of 
this study is to provide a comprehensive review of HRQoL
instruments used in children and adolescents with epilepsy.
METHODS: A literature review was conducted from January
1990–December 2006 using the following databases: Medline,
PsycINFO, and CINAHL using a combination of keywords like
“quality of life”, “epilepsy”, “seizures”, “children”, “adoles-
cents” and “instruments”. The instruments included in the
review were evaluated based on the number of items and
domains, scaling methods, and psychometric properties.
RESULTS: The literature search yielded 13 instruments includ-
ing 4 generic, 7 epilepsy-speciﬁc, and 2 domain-speciﬁc instru-
ments. The most widely used generic, epilepsy-speciﬁc, and
domain-speciﬁc instruments were Impact of Childhood Illness
Scale, Quality of Life in Childhood Epilepsy Questionnaire, and
Hague Restriction in Epilepsy Scale, respectively. The HRQoL
instruments varied widely in the age range (2–18 years), length
of the instruments (10–125 items), scaling methods, respondents
(child or the parent as proxy) and psychometric attributes such
as reliability, validity, and responsiveness. Most of the instru-
ments reviewed exhibited satisfactory internal consistency with
values ranging from 0.7 to 0.9. Also, most instruments reported
test-retest reliability and validity measures like construct, content
and criterion validity. CONCLUSION: The comprehensive
description of all the HRQoL instruments used in children and
adolescents with epilepsy will help researchers and clinicians
select the most appropriate instrument. It is hoped that complete
understanding of the impact of epilepsy on HRQoL can help in
the development of appropriate and effective interventions.
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OBJECTIVES: Restless Legs Syndrome (RLS) is a neurological
disorder that has been found to negatively impact a patient’s
quality of life (QoL). A number of QoL instruments speciﬁcally
designed for people with RLS have appeared in the literature.
The objectives of this study were to provide a comprehensive
review of all the QoL instruments and to evaluate the psycho-
metric properties and appropriateness of these instruments in
RLS. METHODS: A systematic literature search was conducted
by one author among literature published from January 1997
through December 2006 through Pubmed, Ovid, and ProQuest.
The search was completed using terms like quality of life, health
status, questionnaires, measures, scales, and restless leg syn-
drome. After the instruments were identiﬁed, a second search
was performed for studies reporting the psychometric properties
(reliability, validity, and responsiveness) of these instruments.
RESULTS: The search yielded one generic and two disease-spe-
ciﬁc QoL instruments: Short Form-36, Restless Legs Syndrome-
Quality of life questionnaire (RLS-QoL), and International RLS
Study Group (IRLSSG). Five studies were included in the review
that discussed the psychometric properties of these instruments.
These instruments were tested on patients above 18 years of age,
and with a diagnosis of RLS. SF-36 showed high internal con-
sistency (0.76–0.93) and was assessed for content, concurrent,
and criterion validity. The RLS-QoL was assessed for item con-
vergent validity (item-scale correlations of ≥0.4), internal con-
sistency (0.79–0.84), and responsiveness. IRLSSG showed a high
inter-examiner reliability (0.93–0.97), internal consistency of
0.87, and high criterion, concurrent, and discriminant validity.
CONCLUSION: This review conﬁrms a limited, yet emerging
use of QoL instruments in people with RLS. The review provides
information about the availability and quality of available instru-
ments in RLS, which can be of value to clinicians and other deci-
sion-makers in accurately diagnosing and treating RLS.
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OBJECTIVES: Both English and Chinese versions of the 8-item
Parkinson’s Disease Questionnaire (PDQ-8) have demonstrated
validity and reliability. However, the measurement equivalence
